EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-SA 4.0

JNK1 inhibitors target distal B cell receptor signaling and overcome BTK-inhibitor resistance in CLL

Shifa Khaja Saleem iD, Sarah Decker iD, Sandra Kissel iD, Marcus Bauer iD, Dmitry Chernyakov iD, Daniela Bräuer-Hartmann iD, Konrad Aumann iD, Claudia Wickenhauser iD, Marco Herling iD, Oleksandra Skorobohatko iD, Nimitha Mathew iD, Cornelius Schmidt iD und 3 weitere

Journal of Experimental Medicine · 2025

DOI: 10.1084/jem.20230681 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Experimental Medicine, 2025. Verfasst von Shifa Khaja Saleem und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, Freiburg University Medical Center, Albert-Ludwigs-University of Freiburg, Breisgau, Germany. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Agammaglobulinaemia Tyrosine Kinase, Receptors, Antigen, B-Cell, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0). Gefördert von: Deutsche Krebshilfe, Deutsche Forschungsgemeinschaft, José-Carreras.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inhibition of the proximal B cell receptor (BCR) signaling pathway by BTK inhibitors is highly effective in the treatment of CLL, but drug resistance or intolerance occurs. Here, we investigated c-Jun N-terminal protein kinase 1 (JNK1) as an alternative drug target in the distal BCR pathway. JNK1 was preferentially overexpressed and activated in poor prognostic CLL with unmutated IGHV. Proximal BCR inhibition (BTK, PI3K, or SYK inhibitors) or SYK knockdown efficiently dephosphorylated JNK1, identifying JNK1 as a critical BCR downstream kinase in CLL. JNK1 inhibition induced apoptosis in primary CLL cells, resulting in the downregulation of BCL2, MCL1, and c-JUN. JNK1 inhibition in patient-derived CLL xenografted mice and Eµ-TCL1-tg mice prevented CLL progression, reduced splenic infiltration, and restored T cell function and normal hematopoiesis. JNK1 inhibitors even remained effective in ibrutinib refractory CLL. In conclusion, our study revealed JNK1 as a promising drug target in CLL downstream of the BCR, overcoming ibrutinib resistance, blocking the protective microenvironment, and improving CLL-specific immunosuppressive mechanisms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Lymphocytic, Chronic, B-CellAgammaglobulinaemia Tyrosine KinaseReceptors, Antigen, B-CellDrug Resistance, NeoplasmSignal TransductionMitogen-Activated Protein Kinase 8AdenineProtein Kinase InhibitorsPiperidinesHumansAnimalsMiceApoptosisFemalePyrimidinesSyk KinaseMaleMice, Transgenic

Substanzen

Agammaglobulinaemia Tyrosine KinaseReceptors, Antigen, B-CellMitogen-Activated Protein Kinase 8ibrutinibAdenineProtein Kinase InhibitorsPiperidinesBTK protein, humanPyrimidinesSyk Kinase

Autor:innen und Institutionen

  • Department of Hematology and Oncology, Freiburg University Medical Center, Albert-Ludwigs-University of Freiburg, Breisgau, Germany.
  • Institute of Pathology, University Hospital Halle, Martin Luther University Halle-Wittenberg , Halle, Germany.
  • Department of Hematology/Oncology and Stem Cell Transplantation, KIM IV, Martin-Luther University Halle-Wittenberg, Halle, Germany.
  • Department of Pathology, Freiburg University Medical Center, Albert-Ludwigs-University of Freiburg, Breisgau, Germany.
  • Department of Hematology, Cellular Therapy, Hemostaseology and Infectious Diseases, University of Leipzig, Leipzig, Germany.
  • Department of Nuclear Medicine, Freiburg University Medical Center, Albert-Ludwigs-University of Freiburg, Breisgau, Germany.

ORCID-Profile: Shifa Khaja Saleem, Sarah Decker, Sandra Kissel, Marcus Bauer, Dmitry Chernyakov, Daniela Bräuer-Hartmann, Konrad Aumann, Claudia Wickenhauser, Marco Herling, Oleksandra Skorobohatko, Nimitha Mathew, Cornelius Schmidt, Claudius Klein, Marie Follo, Christine Dierks

Förderung

  • Deutsche Krebshilfe
  • Deutsche Forschungsgemeinschaft
  • José-Carreras

Zitieren

APA

Saleem, S. K., Decker, S., Kissel, S., Bauer, M., Chernyakov, D., Bräuer-Hartmann, D., Aumann, K., Wickenhauser, C., Herling, M., Skorobohatko, O., Mathew, N., Schmidt, C., Klein, C., Follo, M., & Dierks, C. (2025). JNK1 inhibitors target distal B cell receptor signaling and overcome BTK-inhibitor resistance in CLL. Journal of Experimental Medicine. https://doi.org/10.1084/jem.20230681

Vancouver

Saleem SK, Decker S, Kissel S, Bauer M, Chernyakov D, Bräuer-Hartmann D, et al. JNK1 inhibitors target distal B cell receptor signaling and overcome BTK-inhibitor resistance in CLL. Journal of Experimental Medicine. 2025. doi:10.1084/jem.20230681

BibTeX
@article{Saleem2025,
  author = {Saleem, Shifa Khaja and Decker, Sarah and Kissel, Sandra and Bauer, Marcus and Chernyakov, Dmitry and Bräuer-Hartmann, Daniela and Aumann, Konrad and Wickenhauser, Claudia and Herling, Marco and Skorobohatko, Oleksandra and Mathew, Nimitha and Schmidt, Cornelius and Klein, Claudius and Follo, Marie and Dierks, Christine},
  title = {JNK1 inhibitors target distal B cell receptor signaling and overcome BTK-inhibitor resistance in CLL},
  journal = {Journal of Experimental Medicine},
  year = {2025},
  doi = {10.1084/jem.20230681}
}
Kostenlos starten →